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Background: Pre-race screening and risk stratification in recreational endurance 
runners may predict adverse events (AEs) during a race.
Aim: To determine if pre-race screening and risk stratification predict AEs during 
a race.
Methods: A total of 29 585 participants (Male 71.1%, average age = 42.1 years; 
Female 28.9%, average age = 40.2 years) at the Two Oceans ultra-marathon races 
(56 km) completed a pre-race medical screening questionnaire and were risk strati-
fied into four pre-specified groups [very high risk (VHR; existing cardiovascular 
disease–CVD:3.2%), high risk (HR; risk factors for CVD:10.5%), intermediate risk 
(IR; existing other chronic disease, medication use or injury:53.3%), and low risk 
(LR:33.0%)]. Race starters, finishers, and medical encounters (ME) were recorded. 
Did-not-start (DNS) rate (per 1000 entrants that did-not-start), did-not-finish (DNF) 
rate (per 1000 starters that did-not-finish), AE rate [per 1000 starters that either DNF 
or had an ME], and ME rate (per 1000 starters with an ME) were compared across 
risk categories.
Results: Adverse events were significantly higher (per 1000 starters; 95%CI) in the 
VHR (68.9; 52.4-89.9:P = .0407) compared with the LR (51.3; 46.5-56.7). The DNS 
rate was significantly different between the IR (190.3; 184.0-196.9) and LR (207.4; 
199.2-216.0: P = .0011). DNF rates were not different in the VHR (56.4; 41.9-75.9) 
compared to LR (44.2; 39.7-49.1: P = .1295), and ME rate was also not different be-
tween risk categories, however, VHR (12.9; 7.0-23.9) was approaching significance 
compared to LR (6.9; 5.2-9.1: P = .0662).
Conclusion: Pre-race medical screening and risk stratification may identify athletes 
at higher risk of AEs. Further studies should be performed in larger cohorts to clarify 
the role of pre-race medical screening in reducing AEs in endurance runners.
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1 |  INTRODUCTION
Due to increased awareness of the health benefits of physical 
activity in the prevention and treatment of non-communicable 
diseases (NCDs),1-5 current guidelines suggest a minimum of 
150 minutes of moderate to vigorous-intensity exercise per 
week.1 Therefore, more people than previously participate 
in moderate to vigorous physical exercise, including mass 
community-based sports events. In distance running events, 
particularly, the number of older athletes participating has 
increased.6 However, during/after participation in vigorous-
intensity exercise there is a higher risk of medical encounters 
(MEs),7,8 including acute myocardial infarctions and sudden 
death.6,9-11 Recent literature has started to document not only 
deaths at mass community-based endurance sports events but 
also moderate and serious life-threatening MEs.8,11 The in-
cidence rate (IR) (per 100 000 race starters) of sudden death 
during/after distance running events is 0.4-3.4,12 with the IR 
of sudden cardiac arrest at least double (2.18).11 The IR of 
serious life-threatening MEs (16.7-155 per 100 000),8,12 and 
all MEs (827-4449 per 100 000),8,12 are considerably higher. 
These data show that documenting only sudden cardiac ar-
rests or deaths during sporting events and represent only the 
“tip of the iceberg” of the total medical burden during/after a 
mass community-based sports event.
Another aspect of distance running events is the “adverse 
events” occurring at events. An adverse event is defined as the 
count of any participant who did-not-finish the event (partici-
pants withdrawing for reasons other than medical, or withdraw-
ing for medical reasons without consulting the medical team)13 
or had a medical encounter13 or both. These outcomes place a 
large burden on the race organizers and medical teams at mass 
community-based events, as well as on the participant them-
selves. Therefore, measures should be implemented to reduce 
adverse events at races, and the data regarding adverse events 
can be used for better race planning.12
The role of pre-exercise screening to identify individuals 
that may be at higher risk for MEs has recently received more 
attention. Many sports federations14,15 and international bodies 
including the International Olympic Committee (IOC)16 and 
the International Paralympic Committee (IPC) either mandate 
or recommend pre-participation screening.14 However, cur-
rently, these screening programs focus mostly on screening 
younger elite athletes,17-19 and concentrate almost exclusively 
on pre-participation cardiac screening (including a resting elec-
trocardiogram) to reduce the risk of acute cardiovascular com-
plications. Although the American Heart Association (AHA)20 
and the European Association for Cardiovascular Prevention 
and Rehabilitation (EACPR)21,22 have developed recommen-
dations for pre-participation screening for master and leisure 
athletes wanting to engage in moderate to vigorous physical 
exercise, these recommendations are rarely executed.
We implemented a pre-participation screening question-
naire (based on the EACPR recommendations) in a sample 
of distance runners21,22 and showed that 31% of participants 
would require a medical assessment prior to the event, with 
16.8% (of the total sample) identified to have suspected 
CVD.23 Recently, we investigated the efficacy of implement-
ing a pre-participation medical screening and an educational 
intervention, based on risk stratification, during the Two 
Oceans Marathon races (21.1 and 56 km running distance)24 
and showed that a pre-screening and an educational interven-
tion decreased the incidence of MEs. Specifically, it reduced 
29% of all MEs and 64% of serious life-threatening MEs.24
Thus, the aim of this study is to determine if pre-race 
medical screening and risk stratification in recreational en-
durance runners can identify athletes at higher risk of ad-
verse events. We hypothesize that ultra-marathon runners 
that are in higher risk stratification categories have a higher 
incidence of adverse events during/after a 56 km running 
race.
2 |  MATERIALS AND METHODS
2.1 | Study design
We conducted cross-sectional analysis of data that we col-
lected prospectively over a 4-year period (2012-2015).
2.2 | Participants and data collection
This study forms part of the SAFER (Strategies to re-
duce adverse medical events For the ExerciseR) studies. 
Participants for this study were all from the Two Oceans 
Ultra-marathon (56km) races, a mass community-based 
running event in South Africa. Entry for the 56  km race 
requires a sub-5  hour 42.2  km-qualifying time. Entrants, 
defined as any runner registering for the races (registra-
tion typically opens 3-5 months before the races), over a 
4-year period (2012-2015) were considered as participants. 
In each of the 4 years, the race entrant data (demographics 
including age, sex, previous participation, and previously 
completed races) and race-day data (number of starters and 
finishers) were obtained. Demographic and race data are 
in the public domain and are available on the race website. 
We analyzed the anonymized data on MEs in runners who 
presented to the medical facilities on race day. All entrant, 
race-day, and ME data were accessed with permission from 
the race medical team and race organizers. Medical facili-
ties consisted of on-route medical stations and the medi-
cal facility at the finish, and the ME definition from the 
2019 consensus statement was used, and only MEs of at 
least moderate severity were included in this study.13 Race 
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physicians recorded accurate and detailed clinical informa-
tion of each ME in a standardized format.
The Research Ethics Committee of the University of Cape 
Town (REC 009/2011 and REC R030/2013) approved the 
protocol and the Research Ethics Committee of the University 
of Pretoria (REC 433/2015) approved the ongoing data col-
lection, and subsequent analysis of the data.
2.3 | Online pre-race medical screening, risk 
stratification, and educational intervention
In this 4-year study period (2012-2015), an intervention was 
implemented for all 56  km race entrants. The intervention 
consisted of a compulsory pre-race medical screening ques-
tionnaire or “self-assessment of risk” (full details have pre-
viously been described).24 The pre-race medical screening 
questionnaire was based on the EACPR recommendations and 
consisted of the following main categories: cardiovascular dis-
ease (CVD), symptoms of CVD, risk factors for CVD, other 
chronic disease, general prescription medication use, medica-
tion use during racing, injury and a past history of collapse 
during racing. Following the screening questionnaire, an ath-
lete's risk was stratified into one of four risk categories (“very 
high” [VHR], “high” [HR], “intermediate” [IR], and “low” 
[LR] risk), using an automated algorithm.24 Athletes complet-
ing the screening were given the opportunity to consent to their 
data being used for research purposes upon completion.
Following risk stratification, if the runner was classified 
into one of the two highest risk categories (VHR or HR) tar-
geted educational material was delivered to the runner via a 
personalized email, and they were specifically advised to seek 
medical clearance prior to the race.24 Furthermore, a general 
educational intervention was conducted through weekly posts 
on the dedicated medical section of the official race website, 
and all runners were sent regular emails to notify them to 
visit the website. No runner was prevented from participating 
in the race by race-organizers or the medical team, and the 
final decision to run on race day was left up to the athlete and 
his/her medical practitioner.
2.4 | Outcome measures
The primary outcome measures were the did-not-start (DNS), 
did-not-finish (DNF), medical encounter (ME), and adverse 
event (AE) rates in each risk category. The outcome meas-
ures were defined as follows: did-not-start rate (DNS: runners 
registering but not starting, per 1000 entrants), did-not-finish 
rate (DNF: runners starting but not finishing the race, per 
1000 starters), medical encounter rate (ME: starters having 
a medical encounter, per 1000 starters), adverse-event rate 
(defined as those that DNF or had an ME, per 1000 starters). 
The objective of the study was to determine if there was an 
association between the applied risk category (based on the 
risk stratification) during the Two Oceans Ultra-marathon 
races (2012-2015) and the above outcome measures.
2.5 | Statistical analysis
All available data were entered into an Excel spreadsheet 
(Microsoft 2010) and then analyzed using the SAS Enterprise 
Guide (V7.13) statistical program. For analyses purposes, the 
data had to be transformed from a wide format to a long for-
mat so that when a runner did-not-finish and had a medical 
encounter it counted for 2 adverse events. All the medical 
complications data were analyzed with a Poisson regression 
model, using a robust error estimator (log link function). This 
cohort consists of correlated data as numerous runners ran 
these races more than once during the 4-year period. The cor-
related structure was accounted for by using an exchangeable 
correlation matrix. This was to estimate the incidence rates 
(IRs) and CIs. Group comparisons and 95% CIs for these IRs 
and differences were also obtained. Poisson regression analy-
ses were conducted to determine the risk stratification asso-
ciated with the development of any medical encounter, any 
adverse event, not starting the race and also not finishing the 
race during this 4-year period. The low risk (LR) stratifica-
tion group was the reference category. In the Poisson context, 
the ratio of these proportions was recast as a ratio of rates 
(rate ratio) for each of the outcomes. These regressions were 
unadjusted as age-group, and gender were already accounted 
for in the four risk stratification groups. Statistical signifi-
cance was accepted at P < .05.
3 |  RESULTS
Over the four years, 29  585 ultra-marathon entrants gave 
consent for their pre-race medical screening data to be used 
for research purposes (70.4% of all ultra-marathon entrants). 
Of the consenting entrants, 71.1% were male, with an aver-
age age of 42.1 years, and the 28.9% females had an average 
age of 40.2 years. Of these, 5589 entrants (18.9%) did-not-
start the race and 23 996 entrants (81.1%) started the race. 
Over the four-year period, 22 964 starters finished the race 
(95.7% starters), 1032 were non-finishers (4.3% starters), 
and 179 medical encounters were recorded. The total num-
ber of adverse events (number of non-finishers and number 
of medical encounters) over the 4-year period was 1211, but 
the total number of runners with AEs were 1191 (some MEs 
were counted separately as DNFs as well). The consenting 
entrants, starters, non-starters, finishers, non-finishers, medi-
cal encounters, and adverse events (n; %) in each risk cat-
egory are presented in Table 1.
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Among all the race starters (n = 23 996), 3.1% were in the 
VHR category, 10.4% in the HR category, and 53.8% were 
classified in the IR category.
3.1 | Did-Not-Start (DNS) per 1000 
entrants, Did-Not-Finish (DNF), Medical 
Encounter (ME), Adverse Event (AE) per 
1000 starters
The did-not-start rate (per 1000) of entrants, per risk category 
over four years, is presented in Table 2. The did-not-finish, 
medical encounter, and adverse-event rate per 1000 race 
starters for the four years are also presented in Table 2.
There was an overall significant difference in DNS rates 
between risk categories (P = .008).
There was no significant overall difference in DNF rates 
between risk categories (P =  .366), ME rates between risk 
categories (P = .5076) or AE rates between risk categories 
(P = .278). However, for DNF and AE rates there were sig-
nificant differences between specific risk categories.
There was no apparent difference between risk categories’ 
relationship to environmental conditions (WBGT) over the 
years (Figure S1).
4 |  DISCUSSION
The main finding of this study was that the AE rate was signifi-
cantly higher in a VHR category [runners reporting known car-
diovascular disease (CVD) or symptoms of CVD] compared 
with the LR category in ultra-marathon runners who were risk 
stratified into four risk categories using a pre-screening medi-
cal questionnaire and risk stratification process. We also note 
that DNF and ME rates were highest in the VHR category, al-
though these rates were not statistically different. Furthermore, 
the DNS rate between groups was also significantly different.
In this study, we show that existing cardiovascular dis-
ease (CVD) or symptoms of CVD23 is associated with a 30% 
increased risk of an adverse event in ultra-marathon race en-
trants. To our knowledge, no other study has investigated if 
pre-race risk stratification, based on a history of pre-exist-
ing diseases, is associated with an increased risk for adverse 
events in distance running events. International pre-participa-
tion health screening guidelines and recommendations, with 
risk stratification, have been developed and are promoted by 
international organizations.25-27 However, the implementa-
tion of these guidelines and recommendations has not been 
applied, specifically in mass community-based sports events. 
Our data illustrate the potential value of pre-race medical 
screening and risk stratification to identify athletes “at risk” 
for adverse events. This information will also be of value to 














































































































































































































































































































































































































































































































   | 1209SEWRY Et al.
adverse events (ie a medical encounter, or participants who 
do not finish the event) on race day.
The DNF and ME rates were highest in the VHR cate-
gory, but these rates were not statistically different across risk 
categories. This may be because the sample size of medical 
encounters and DNFs was too small to show significant differ-
ences and we acknowledge that as a limitation. Future studies 
with larger sample sizes are required to address this limita-
tion. The results may have also been affected by the educa-
tional intervention. Specifically, all runners in the VHR and 
HR risk categories received individualized targeted pre-race 
educational material. This consisted of advice to: (1) undergo 
a medical assessment and clearance by a medical doctor prior 
to the race, (2) be aware of possible symptoms of CVD while 
exercising, and (3) stop exercise if these symptoms occur 
during running. Runners in all categories also received gen-
eral education material via the race website. We could not re-
cord the reasons why runners did-not-finish the race in this 
study. Therefore, the results of this study must be interpreted 
with this limitation in mind. However, we note that, despite 
the targeted intervention in the VHR and HR categories, the 
DNF, ME, and AE rates in the VHR was still the highest com-
pared with all the other categories. We can speculate that, if 
there was no pre-race screening and educational intervention, 
runners in the VHR, HR, and IR would have even higher DNF, 
ME, and AE rates, and thus we may have underestimated the 
effect of pre-race medical screening in the present study. 
However, to conduct a study where pre-race screening to risk 
stratify entrants is done but without an educational interven-
tion, would pose a very significant ethical challenge.
It could be argued that the pre-race screening and educational 
intervention would increase the DNS in the VHR and HR cat-
egories, because entrants in these groups were advised to seek 
medical clearance from their medical practitioner before the 
race. However, we note that the DNS rate was not higher in the 
VHR or HR groups, but rather that the DNS rate was highest in 
T A B L E  2  The did-not-start rate (per 1000 entrants: 95% CI) per risk category of entrants and did-not-finish, medical encounter, and adverse 
event rate (per 1000 starters: 95% CI) per risk category of starters
Risk category DNS rate (per 1000 entrants) 95% CI
Rate 
ratio* 95% CI P-value*
Very high risk 205.4 180.4 233.8 1.0 0.9 1.1 .888
High risk 205.4 191.1 220.9 1.0 0.9 1.1 .822
Intermediate risk 190.3 184.0 196.9 0.9 0.9 1.0 .001
Low risk 207.4 199.2 216.0 - - - -
Risk category DNF rate (per 1000 starters) 95% CI
Rate 
ratio* 95% CI P-value*
Very high risk 56.4 41.9 75.9 1.3 0.9 1.8 .130
High risk 48.6 40.4 58.5 1.1 0.9 1.4 .377
Intermediate risk 43.3 39.8 47.1 1.0 0.9 1.1 .756
Low risk 44.2 39.7 49.1 - - - -
Risk category
Medical encounter rate (per 1000 
starters) 95% CI
Rate 
ratio* 95% CI P-value*
Very high risk 12.9 7.0 23.8 1.9 1.0 3.7 .066
High risk 6.8 4.2 10.9 1.0 0.6 1.7 .956
Intermediate risk 7.6 6.2 9.3 1.1 0.8 1.6 .567
Low risk 6.9 5.2 9.1 - - - -
Risk category
Adverse-event rate (per 1000 
starters) 95% CI
Rate 
ratio* 95% CI P-value*
Very high risk 68.7 52.4 89.9 1.3 1.0 1.8 .047
High risk 55.5 46.7 65.0 1.1 0.9 1.3 .435
Intermediate risk 51.1 47.3 55.3 1.0 0.9 1.1 .956
Low risk 51.3 46.5 56.7 - - - -
Total non-starters: n = 5589.
Total non-finishers: n = 1032.
Total medical encounters: n = 179.
Total runners with adverse events: n = 1191.
*Compared to the Low-Risk group. 
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the LR group. We acknowledge that we do not present data to 
show that entrants in the VHR and HR group sought medical 
clearance from their medical practitioner and if they did, whether 
they adhered to advice given by the medical practitioner. We in-
terpret these DNS data to show that, over the 4-year period, the 
pre-race screening and intervention did not result in a significant 
“self-exclusion” of runners in the VHR and HR categories from 
starting the race. Rather, we suggest that runners in these two 
categories chose to start the races, but were equipped with the 
correct information to make their own decisions about partic-
ipation in these races. Furthermore, only a selected few of the 
highest risk (not affecting the overall participation rate) chose 
not to participate. We suggest that future studies should further 
investigate these runners that are identified as VHR or HR, and 
what medical clearance or lack thereof they sought.
The strengths of this study include the large homogenous 
sample size of 56km race entrants, and that the data were col-
lected prospectively over four years. To our knowledge, this 
is the largest study of this nature and the first study to iden-
tify risk stratification as a possible predictor of adverse events. 
Medical data were collected by medical doctors. We also had 
comprehensive information on all participants, regarding entry 
data and their pre-screening medical questionnaire data for risk 
stratification. Previous research has not had access to such in 
depth knowledge of the participants’ medical history, and only 
had access to race-day data and basic entry information.28-32
One of the limitations of the study is that it was a prospec-
tive cross-sectional study and not a randomized controlled 
trial. As mentioned, the cohort used in this study had been 
exposed to an intervention, and the results could have been 
affected by the advice distributed during the intervention. 
Therefore, the results of this study must be interpreted with 
this study limitation in mind. The study is under-powered 
and would require approximately 41 000 entrants to find a 
significant effect in all three outcomes. Another limitation 
is that all the pre-race medical screening data of the partici-
pants was self-reported, and there were participants who did 
not give consent, so there could also be a selection bias of “at 
risk” individuals not willing to reveal their medical history 
for research. The specific risk factors responsible for the as-
sociation between the outcomes (such as adverse events, did-
not-finish, and medical encounters) and the risk stratification 
categories found in this cohort should also be further investi-
gated. We acknowledge that further potential external factors 
unrelated to health status could influence the AE/ME/DNF 
rates in risk categories (such as environmental conditions)33 
and should be further explored in future studies.
5 |  PERSPECTIVE
In summary, this study shows that risk stratification of ultra-
marathon runners using a pre-screening medical questionnaire 
enables identification of a very high risk (VHR) group of 
runners that has a 30% greater risk of an adverse event dur-
ing a race. Pre-race screening and risk stratification may aid 
the medical staff to better prepare for medical care on race 
day. Future studies (using a larger sample and a follow-up) 
should investigate which specific risk factors contributed to 
the risk of adverse events, did-not-finish, and medical en-
counter rates in distance running events, with the goal of re-
fining pre-exercise medical screening questionnaires.
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